Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Followed By 23-valent Pneumococcal Polysaccharide Vaccine In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years And Older

NCT00980655 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00980655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00980655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Followed By 23-valent Pneumococcal Polysaccharide Vaccine In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years And Older
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 18, 2010
Completion date
May 16, 2013
Enrollment
251 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

vaccines, pneumococcal conjugate vaccine